MSL
EPZM

Mackay Shields LLC’s Epizyme, Inc EPZM Stock Holding History

Mackay Shields LLC’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-85,700
Closed -$746K – 1446
2021
Q1 		$746K Sell
85,700
-18,900
-18% -$196K 0.01% 1091
2020
Q4 		$1.14M Sell
104,600
-2,600
-2% -$32.1K 0.01% 1050
2020
Q3 		$1.28M Buy
107,200
+23,300
+28% +$312K 0.01% 954
2020
Q2 		$1.35M Buy
83,900
+26,300
+46% +$459K 0.01% 922
2020
Q1 		$894K Buy
+57,600
New +$1.24M 0.01% 985

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Mackay Shields LLC's EPZM Position: Q2 2021 in Review

Mackay Shields LLC sold out of Epizyme, Inc (EPZM) in Q2 2021, closing a stake of 85,700 shares — an estimated $746K sold.

Mackay Shields LLC first reported a position in EPZM in Q1 2020 and held it in 5 quarters. The position peaked at $1.35M in Q2 2020. 126 funds tracked by Wall St. Rank hold EPZM as of Q2 2021.

  • Mackay Shields LLC reported no remaining Epizyme, Inc position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 85,700 Epizyme, Inc shares in Q2 2021, an estimated $746K.
  • Mackay Shields LLC first reported a position in Epizyme, Inc in Q1 2020 and held it in 5 quarters.
  • Mackay Shields LLC's Epizyme, Inc position peaked at $1.35M in Q2 2020.
  • 126 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.